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Background
Systemic onset juvenile idiopathic arthritis (SoJIA) is an
acquired auto-inflammatory disease characterized by
systemic inflammation and innate immune activation
reflected by uncontrolled production of cytokines such
as IL-1, IL- 6 and IL-18. In SoJIA, NK cell function is
severely hampered despite high levels of IL-18.
We recently found that defective phosphorylation of
the IL-18 receptor beta is responsible for the deficient
IL-18-NK cell axis in SoJIA.
Aim
To study first line treatment with recombinant IL-1
receptor antagonist (rIL-1RA, Anakinra) in 16 newly
diagnosed and steroid naïve systemic onset JIA patients.
Materials and methods
Clinical outcome was measured using ACRp70 and
ACRp90. Furthermore, NK cell lytic function, inflamma-
some activity and cytokine levels in plasma were
assessed during follow up (max 3 years).
Results
Here we show that patients with SoJIA have increased
inflammasome activation leading to elevated IL-18 levels.
First line treatment in steroid naïve patients, with rIL-1RA
effectively down-regulated IL-18 levels through suppres-
sion of inflammasome activation and led to rapid resolu-
tion of clinical features in 87% (ACRp90) of patients.
Furthermore, using rIL-1RA as first line treatment
approach the defective IL-18-NK cell axis is restored as
shown by improved lytic NK cell function and regaining of
the NK cell responsiveness to IL-18 stimulation.
Conclusions
These data suggest that the mechanisms of inflamma-
tory control induced by rIL-1RA in SoJIA patients
involves more than blocking IL-1R. Our data show that
rIL-1RA directly targets the inflammasome and restores
the IL-18 NK cell axis as well.
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